

**Ezetimibe / Simvastatin Formulation**

Version            Revision Date:            SDS Number:            Date of last issue: 04/24/2019  
4.2                09/13/2019              28109-00014            Date of first issue: 11/04/2014

---

**SECTION 1. IDENTIFICATION**

Product name                            : Ezetimibe / Simvastatin Formulation  
Other means of identification        : No data available

**Manufacturer or supplier's details**

Company name of supplier        : Merck & Co., Inc  
Address                                 : 2000 Galloping Hill Road  
    Kenilworth - New Jersey - U.S.A. 07033  
Telephone                             : 908-740-4000  
Telefax                                 : 908-735-1496  
Emergency telephone               : 1-908-423-6000  
E-mail address                        : EHSDATASTEWARD@merck.com

**Recommended use of the chemical and restrictions on use**

Recommended use                    : Pharmaceutical

---

**SECTION 2. HAZARDS IDENTIFICATION****GHS classification in accordance with the Hazardous Products Regulations**

Skin irritation                         : Category 2  
Skin sensitization                    : Category 1  
Specific target organ toxicity       : Category 1 (Liver, muscle, optic nerve, Eye)  
- repeated exposure

**GHS label elements**

Hazard pictograms                    :



Signal Word                            : Danger

Hazard Statements                    : H315 Causes skin irritation.  
    H317 May cause an allergic skin reaction.  
    H372 Causes damage to organs (Liver, muscle, optic nerve,  
    Eye) through prolonged or repeated exposure.

Precautionary Statements         : **Prevention:**  
    P260 Do not breathe dust/ fume/ gas/ mist/ vapors/ spray.  
    P264 Wash skin thoroughly after handling.  
    P270 Do not eat, drink or smoke when using this product.  
    P272 Contaminated work clothing should not be allowed out of  
    the workplace.  
    P280 Wear protective gloves.  
**Response:**  
    P302 + P352 IF ON SKIN: Wash with plenty of water.  
    P314 Get medical advice/ attention if you feel unwell.  
    P333 + P313 If skin irritation or rash occurs: Get medical advice/

## Ezetimibe / Simvastatin Formulation

Version 4.2      Revision Date: 09/13/2019      SDS Number: 28109-00014      Date of last issue: 04/24/2019  
 Date of first issue: 11/04/2014

attention.  
 P362 + P364 Take off contaminated clothing and wash it before reuse.

### Disposal:

P501 Dispose of contents/ container to an approved waste disposal plant.

### Other hazards

Dust contact with the eyes can lead to mechanical irritation.  
 May form explosive dust-air mixture during processing, handling or other means.

## SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

### Components

Chemical name	CAS-No.	Concentration (% w/w)
Cellulose	9004-34-6	>= 10 - < 30
Ezetimibe	163222-33-1	>= 10 - < 30
Simvastatin	79902-63-9	>= 10 - < 30
Magnesium stearate	557-04-0	>= 1 - < 5

Actual concentration or concentration range is withheld as a trade secret

## SECTION 4. FIRST AID MEASURES

- General advice : In the case of accident or if you feel unwell, seek medical advice immediately.  
 When symptoms persist or in all cases of doubt seek medical advice.
- If inhaled : If inhaled, remove to fresh air.  
 Get medical attention if symptoms occur.
- In case of skin contact : In case of contact, immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.  
 Get medical attention.  
 Wash clothing before reuse.  
 Thoroughly clean shoes before reuse.
- In case of eye contact : If in eyes, rinse well with water.  
 Get medical attention if irritation develops and persists.
- If swallowed : If swallowed, DO NOT induce vomiting.  
 Get medical attention if symptoms occur.  
 Rinse mouth thoroughly with water.
- Most important symptoms and effects, both acute and delayed : Causes skin irritation.  
 May cause an allergic skin reaction.  
 Causes damage to organs through prolonged or repeated exposure.  
 Dust contact with the eyes can lead to mechanical irritation.
- Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
- Notes to physician : Treat symptomatically and supportively.

**Ezetimibe / Simvastatin Formulation**

Version            Revision Date:            SDS Number:            Date of last issue: 04/24/2019  
4.2                09/13/2019              28109-00014            Date of first issue: 11/04/2014

---

**SECTION 5. FIRE-FIGHTING MEASURES**

- Suitable extinguishing media : Water spray  
Alcohol-resistant foam  
Carbon dioxide (CO<sub>2</sub>)  
Dry chemical
- Unsuitable extinguishing media : None known.
- Specific hazards during fire fighting : Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.  
Exposure to combustion products may be a hazard to health.
- Hazardous combustion products : Carbon oxides  
Nitrogen oxides (NO<sub>x</sub>)  
Fluorine compounds  
Metal oxides
- Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.  
Use water spray to cool unopened containers.  
Remove undamaged containers from fire area if it is safe to do so.  
Evacuate area.
- Special protective equipment for fire-fighters : In the event of fire, wear self-contained breathing apparatus.  
Use personal protective equipment.
- 

**SECTION 6. ACCIDENTAL RELEASE MEASURES**

- Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.  
Follow safe handling advice and personal protective equipment recommendations.
- Environmental precautions : Discharge into the environment must be avoided.  
Prevent further leakage or spillage if safe to do so.  
Retain and dispose of contaminated wash water.  
Local authorities should be advised if significant spillages cannot be contained.
- Methods and materials for containment and cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal.  
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).  
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.  
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.  
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.
- 

**SECTION 7. HANDLING AND STORAGE**

## Ezetimibe / Simvastatin Formulation

Version 4.2      Revision Date: 09/13/2019      SDS Number: 28109-00014      Date of last issue: 04/24/2019  
 Date of first issue: 11/04/2014

- Technical measures : Static electricity may accumulate and ignite suspended dust causing an explosion.  
 Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.
- Local/Total ventilation : Use only with adequate ventilation.
- Advice on safe handling : Do not get on skin or clothing.  
 Do not breathe dust.  
 Do not swallow.  
 Avoid contact with eyes.  
 Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment  
 Minimize dust generation and accumulation.  
 Keep container closed when not in use.  
 Keep away from heat and sources of ignition.  
 Take precautionary measures against static discharges.  
 Take care to prevent spills, waste and minimize release to the environment.
- Conditions for safe storage : Keep in properly labeled containers.  
 Store in accordance with the particular national regulations.
- Materials to avoid : Do not store with the following product types:  
 Strong oxidizing agents  
 Organic peroxides  
 Explosives  
 Gases

### SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

#### Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Cellulose	9004-34-6	TWA	10 mg/m <sup>3</sup>	CA AB OEL
		TWA (Total dust)	10 mg/m <sup>3</sup>	CA BC OEL
		TWA (respirable dust fraction)	3 mg/m <sup>3</sup>	CA BC OEL
		TWAEV (total dust)	10 mg/m <sup>3</sup>	CA QC OEL
		TWA	10 mg/m <sup>3</sup>	ACGIH
Ezetimibe	163222-33-1	TWA	25 µg/m <sup>3</sup> (OEB 3)	Internal
		Wipe limit	250 µg/100 cm <sup>2</sup>	Internal
Simvastatin	79902-63-9	TWA	25 µg/m <sup>3</sup> (OEB 3)	Internal
	Further information: DSEN			
		Wipe limit	250 µg/100 cm <sup>2</sup>	Internal
Magnesium stearate	557-04-0	TWA	10 mg/m <sup>3</sup>	CA AB OEL
		TWA	10 mg/m <sup>3</sup>	CA BC OEL
		TWA (Inhalable fraction)	10 mg/m <sup>3</sup>	ACGIH
		TWA	3 mg/m <sup>3</sup>	ACGIH

## Ezetimibe / Simvastatin Formulation

Version 4.2      Revision Date: 09/13/2019      SDS Number: 28109-00014      Date of last issue: 04/24/2019  
 Date of first issue: 11/04/2014

		(Respirable fraction)		
--	--	-----------------------	--	--

**Engineering measures** : All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).  
 Minimize open handling.

### Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type : Particulates type  
 Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.  
 Eye protection : Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection : Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

## SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : powder  
 Color : No data available  
 Odor : No data available

# SAFETY DATA SHEET



## Ezetimibe / Simvastatin Formulation

Version 4.2      Revision Date: 09/13/2019      SDS Number: 28109-00014      Date of last issue: 04/24/2019  
Date of first issue: 11/04/2014

---

Odor Threshold : No data available

pH : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling range : No data available

Flash point : No data available

Evaporation rate : No data available

Flammability (solid, gas) : May form explosive dust-air mixture during processing, handling or other means.

Flammability (liquids) : No data available

Upper explosion limit / Upper flammability limit : No data available

Lower explosion limit / Lower flammability limit : No data available

Vapor pressure : No data available

Relative vapor density : No data available

Relative density : No data available

Solubility(ies)  
Water solubility : No data available

Partition coefficient: n-octanol/water : No data available

Autoignition temperature : No data available

Decomposition temperature : No data available

Viscosity  
Viscosity, kinematic : No data available

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : No data available

Particle size : No data available

---

### SECTION 10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard.



**Ezetimibe / Simvastatin Formulation**

Version 4.2      Revision Date: 09/13/2019      SDS Number: 28109-00014      Date of last issue: 04/24/2019  
Date of first issue: 11/04/2014

---

**Magnesium stearate:**

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg  
Method: OECD Test Guideline 423  
Assessment: The substance or mixture has no acute oral toxicity  
Remarks: Based on data from similar materials

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg  
Remarks: Based on data from similar materials

**Skin corrosion/irritation**

Causes skin irritation.

**Components:****Ezetimibe:**

Species : Rabbit  
Result : No skin irritation

**Simvastatin:**

Species : Rabbit  
Remarks : Moderate skin irritation

**Magnesium stearate:**

Species : Rabbit  
Result : No skin irritation  
Remarks : Based on data from similar materials

**Serious eye damage/eye irritation**

Not classified based on available information.

**Components:****Ezetimibe:**

Species : Rabbit  
Result : No eye irritation

**Simvastatin:**

Species : Rabbit  
Remarks : slight irritation

**Magnesium stearate:**

Species : Rabbit  
Result : No eye irritation  
Remarks : Based on data from similar materials





**Ezetimibe / Simvastatin Formulation**

Version 4.2      Revision Date: 09/13/2019      SDS Number: 28109-00014      Date of last issue: 04/24/2019  
Date of first issue: 11/04/2014

---

Genotoxicity in vivo : Test Type: Micronucleus test  
Species: Mouse  
Cell type: Bone marrow  
Application Route: Oral  
Result: negative

**Simvastatin:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Test Type: Alkaline elution assay  
Result: negative

Test Type: Chromosomal aberration  
Result: negative

Test Type: In vitro mammalian cell gene mutation test  
Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test  
Species: Mouse  
Application Route: Oral  
Result: negative

Germ cell mutagenicity - Assessment : Weight of evidence does not support classification as a germ cell mutagen.

**Magnesium stearate:**

Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test  
Result: negative  
Remarks: Based on data from similar materials

Test Type: Chromosome aberration test in vitro  
Method: OECD Test Guideline 473  
Result: negative  
Remarks: Based on data from similar materials

Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative  
Remarks: Based on data from similar materials

**Carcinogenicity**

Not classified based on available information.

**Components:****Cellulose:**

Species : Rat  
Application Route : Ingestion  
Exposure time : 72 weeks  
Result : negative

## Ezetimibe / Simvastatin Formulation

Version 4.2      Revision Date: 09/13/2019      SDS Number: 28109-00014      Date of last issue: 04/24/2019  
 Date of first issue: 11/04/2014

---

### Ezetimibe:

Species : Rat, female  
 Application Route : oral (feed)  
 Exposure time : 104 weeks  
 Result : negative

Species : Rat, male  
 Application Route : oral (feed)  
 Exposure time : 104 weeks  
 Result : negative

Species : Mouse  
 Application Route : oral (feed)  
 Exposure time : 104 weeks  
 Result : negative

### Simvastatin:

Species : Mouse  
 Application Route : Oral  
 Exposure time : < 92 weeks  
 Target Organs : Harderian gland  
 Tumor Type : Liver, Lungs  
 Remarks : The significance of these findings for humans is not certain.

Species : Rat  
 Application Route : Oral  
 Exposure time : 2 Years  
 Tumor Type : Liver, Thyroid  
 Remarks : The significance of these findings for humans is not certain.

### Reproductive toxicity

Not classified based on available information.

### Components:

#### Cellulose:

Effects on fertility : Test Type: One-generation reproduction toxicity study  
 Species: Rat  
 Application Route: Ingestion  
 Result: negative

Effects on fetal development : Test Type: Fertility/early embryonic development  
 Species: Rat  
 Application Route: Ingestion  
 Result: negative

#### Ezetimibe:

Effects on fertility : Test Type: Fertility/early embryonic development  
 Species: Rat, male and female  
 Fertility: NOAEL: > 1,000 mg/kg body weight  
 Result: No effects on fertility., No fetotoxicity.

Effects on fetal development : Test Type: Development

**Ezetimibe / Simvastatin Formulation**

Version 4.2      Revision Date: 09/13/2019      SDS Number: 28109-00014      Date of last issue: 04/24/2019  
Date of first issue: 11/04/2014

---

Species: Rat  
Application Route: Oral  
Developmental Toxicity: NOAEL: > 1,000 mg/kg body weight  
Result: No adverse effects.

Test Type: Development  
Species: Rabbit  
Application Route: Oral  
Developmental Toxicity: NOAEL: > 1,000 mg/kg body weight  
Result: No adverse effects.

**Simvastatin:**

Effects on fertility : Test Type: Fertility  
Species: Rat, male  
Application Route: Oral  
Fertility: LOAEL: 25 mg/kg body weight

Effects on fetal development : Test Type: Embryo-fetal development  
Species: Rat  
Application Route: Oral  
Embryo-fetal toxicity.: NOAEL: 25 mg/kg body weight  
Result: No teratogenic effects., No adverse effects.

Test Type: Embryo-fetal development  
Species: Rabbit  
Application Route: Oral  
Embryo-fetal toxicity.: NOAEL: 10 mg/kg body weight  
Result: No teratogenic effects., No adverse effects.

Test Type: Embryo-fetal development  
Species: Rat  
Application Route: Oral  
Embryo-fetal toxicity.: LOAEL: 60 mg/kg body weight  
Result: Teratogenic potential.  
Remarks: Based on data from similar materials

**Magnesium stearate:**

Effects on fertility : Test Type: Combined repeated dose toxicity study with the reproduction/developmental toxicity screening test  
Species: Rat  
Application Route: Ingestion  
Method: OECD Test Guideline 422  
Result: negative  
Remarks: Based on data from similar materials

Effects on fetal development : Test Type: Embryo-fetal development  
Species: Rat  
Application Route: Ingestion  
Result: negative  
Remarks: Based on data from similar materials

**STOT-single exposure**

Not classified based on available information.

## Ezetimibe / Simvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/24/2019
4.2	09/13/2019	28109-00014	Date of first issue: 11/04/2014

---

### STOT-repeated exposure

Causes damage to organs (Liver, muscle, optic nerve, Eye) through prolonged or repeated exposure.

#### Components:

##### Simvastatin:

Target Organs	:	Liver, muscle, optic nerve, Eye
Assessment	:	Causes damage to organs through prolonged or repeated exposure.

### Repeated dose toxicity

#### Components:

##### Cellulose:

Species	:	Rat
NOAEL	:	>= 9,000 mg/kg
Application Route	:	Ingestion
Exposure time	:	90 Days

##### Ezetimibe:

Species	:	Dog
NOAEL	:	1,000 mg/kg
Application Route	:	Oral
Exposure time	:	90 d
Remarks	:	No significant adverse effects were reported

Species	:	Rat
NOAEL	:	1,500 mg/kg
Application Route	:	Oral
Exposure time	:	90 d
Remarks	:	No significant adverse effects were reported

Species	:	Mouse
NOAEL	:	500 mg/kg
Application Route	:	Oral
Exposure time	:	90 d
Remarks	:	No significant adverse effects were reported

Species	:	Dog
NOAEL	:	300 mg/kg
Application Route	:	Oral
Exposure time	:	1 y
Remarks	:	No significant adverse effects were reported

##### Simvastatin:

Species	:	Rat
NOAEL	:	5 mg/kg
LOAEL	:	30 mg/kg
Application Route	:	Oral
Exposure time	:	14 - 104 Weeks
Target Organs	:	Liver, Testis, Musculo-skeletal system, Eye

**Ezetimibe / Simvastatin Formulation**

Version 4.2      Revision Date: 09/13/2019      SDS Number: 28109-00014      Date of last issue: 04/24/2019  
Date of first issue: 11/04/2014

---

Species : Dog  
LOAEL : 10 mg/kg  
Application Route : Oral  
Exposure time : 14 - 104 Weeks  
Target Organs : Liver, Testis, Eye

Species : Rabbit  
NOAEL : 30 mg/kg  
LOAEL : 50 mg/kg  
Application Route : Oral  
Target Organs : Liver, Kidney

**Magnesium stearate:**

Species : Rat  
NOAEL : > 100 mg/kg  
Application Route : Ingestion  
Exposure time : 90 Days  
Remarks : Based on data from similar materials

**Aspiration toxicity**

Not classified based on available information.

**Components:****Ezetimibe:**

Not applicable

**Experience with human exposure****Components:****Ezetimibe:**

Ingestion : Symptoms: Headache, Nausea, Vomiting, Diarrhea, flatulence, muscle pain, upper respiratory tract infection, Back pain, joint pain

**Simvastatin:**

Skin contact : Remarks: May produce an allergic reaction.  
Ingestion : Target Organs: Liver  
Symptoms: upper respiratory tract infection, Headache, Abdominal pain, constipation, Nausea  
Target Organs: Musculo-skeletal system

---

**SECTION 12. ECOLOGICAL INFORMATION****Ecotoxicity****Components:****Cellulose:**

Toxicity to fish : LC50 (Oryzias latipes (Japanese medaka)): > 100 mg/l  
Exposure time: 48 h  
Remarks: Based on data from similar materials

**Ezetimibe / Simvastatin Formulation**

Version 4.2      Revision Date: 09/13/2019      SDS Number: 28109-00014      Date of last issue: 04/24/2019  
Date of first issue: 11/04/2014

---

**Ezetimibe:**

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): > 0.125 mg/l  
Exposure time: 96 h  
Method: OECD Test Guideline 203  
Remarks: No toxicity at the limit of solubility.

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 4 mg/l  
Exposure time: 48 h  
Method: OECD Test Guideline 202  
Remarks: No toxicity at the limit of solubility.

Toxicity to algae/aquatic plants : EC50 (Pseudokirchneriella subcapitata (green algae)): > 0.317 mg/l  
Exposure time: 96 h  
Method: OECD Test Guideline 201  
Remarks: No toxicity at the limit of solubility.

NOEC (Pseudokirchneriella subcapitata (green algae)): 0.317 mg/l  
Exposure time: 96 h  
Method: OECD Test Guideline 201  
Remarks: No toxicity at the limit of solubility.

Toxicity to fish (Chronic toxicity) : NOEC (Pimephales promelas (fathead minnow)): 0.051 mg/l  
Exposure time: 33 d  
Method: OECD Test Guideline 210  
NOEC (Cyprinodon variegatus (sheepshead minnow)): 4 mg/l  
Exposure time: 7 d  
Remarks: No toxicity at the limit of solubility.

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 0.282 mg/l  
Exposure time: 21 d  
Remarks: No toxicity at the limit of solubility.

Toxicity to microorganisms : EC50: > 4.4 mg/l  
Exposure time: 3 h  
Test Type: Respiration inhibition  
Method: OECD Test Guideline 209  
Remarks: No toxicity at the limit of solubility.

NOEC: 4.4 mg/l  
Exposure time: 3 h  
Test Type: Respiration inhibition  
Method: OECD Test Guideline 209  
Remarks: No toxicity at the limit of solubility.

**Simvastatin:**

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): 2.91 mg/l  
Exposure time: 96 h  
Method: OECD Test Guideline 203

Toxicity to daphnia and other : EC50 (Daphnia magna (Water flea)): 3.5 mg/l

## Ezetimibe / Simvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/24/2019
4.2	09/13/2019	28109-00014	Date of first issue: 11/04/2014

---

aquatic invertebrates		Exposure time: 48 h Method: OECD Test Guideline 202
Toxicity to algae/aquatic plants	:	EC50 (Pseudokirchneriella subcapitata (green algae)): > 25 mg/l Exposure time: 96 h  NOEC (Pseudokirchneriella subcapitata (green algae)): 25 mg/l Exposure time: 96 h
Toxicity to microorganisms	:	EC50: > 30 mg/l Exposure time: 3 h Test Type: Respiration inhibition Method: OECD Test Guideline 209  NOEC: 21 mg/l Exposure time: 3 h Test Type: Respiration inhibition Method: OECD Test Guideline 209

### Magnesium stearate:

Toxicity to fish	:	LC50 (Leuciscus idus (Golden orfe)): > 100 mg/l Exposure time: 48 h Method: DIN 38412 Remarks: Based on data from similar materials
Toxicity to daphnia and other aquatic invertebrates	:	EL50 (Daphnia magna (Water flea)): > 1 mg/l Exposure time: 47 h Test substance: Water Accommodated Fraction Method: Directive 67/548/EEC, Annex V, C.2. Remarks: Based on data from similar materials No toxicity at the limit of solubility.
Toxicity to algae/aquatic plants	:	EL50 (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l Exposure time: 72 h Test substance: Water Accommodated Fraction Method: OECD Test Guideline 201 Remarks: Based on data from similar materials No toxicity at the limit of solubility.  NOELR (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l Exposure time: 72 h Test substance: Water Accommodated Fraction Method: OECD Test Guideline 201 Remarks: Based on data from similar materials
Toxicity to microorganisms	:	EC10 (Pseudomonas putida): > 100 mg/l Exposure time: 16 h Test substance: Water Accommodated Fraction Remarks: Based on data from similar materials



**Ezetimibe / Simvastatin Formulation**

Version 4.2      Revision Date: 09/13/2019      SDS Number: 28109-00014      Date of last issue: 04/24/2019  
Date of first issue: 11/04/2014

---

**Persistence and degradability****Components:****Cellulose:**

Biodegradability : Result: Readily biodegradable.

**Ezetimibe:**

Biodegradability : Result: Not readily biodegradable.  
Biodegradation: 6.8 %  
Exposure time: 28 d

Stability in water : Hydrolysis: 50 %(4.5 d)  
Method: OECD Test Guideline 111

**Simvastatin:**

Biodegradability : Result: rapidly degradable

Stability in water : Hydrolysis: 50 %(3.2 d)

**Magnesium stearate:**

Biodegradability : Result: Not biodegradable.  
Remarks: Based on data from similar materials

**Bioaccumulative potential****Components:****Ezetimibe:**

Bioaccumulation : Species: Lepomis macrochirus (Bluegill sunfish)  
Bioconcentration factor (BCF): 173  
Exposure time: 97 d  
Method: OECD Test Guideline 305

Partition coefficient: n-octanol/water : log Pow: 4.36

**Simvastatin:**

Partition coefficient: n-octanol/water : log Pow: > 4.07

**Magnesium stearate:**

Partition coefficient: n-octanol/water : log Pow: > 4

**Mobility in soil****Components:****Ezetimibe:**

Distribution among environmental compartments : log Koc: 4.35  
Method: OECD Test Guideline 106



## Ezetimibe / Simvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/24/2019
4.2	09/13/2019	28109-00014	Date of first issue: 11/04/2014

---

	N.O.S. (Ezetimibe, Simvastatin)
Class	: 9
Packing group	: III
Labels	: 9
ERG Code	: 171
Marine pollutant	: yes(Ezetimibe, Simvastatin)

### Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

---

## SECTION 15. REGULATORY INFORMATION

### The ingredients of this product are reported in the following inventories:

AICS	: not determined
DSL	: not determined
IECSC	: not determined

---

## SECTION 16. OTHER INFORMATION

### Full text of other abbreviations

ACGIH	: USA. ACGIH Threshold Limit Values (TLV)
CA AB OEL	: Canada. Alberta, Occupational Health and Safety Code (table 2: OEL)
CA BC OEL	: Canada. British Columbia OEL
CA QC OEL	: Québec. Regulation respecting occupational health and safety, Schedule 1, Part 1: Permissible exposure values for airborne contaminants
ACGIH / TWA	: 8-hour, time-weighted average
CA AB OEL / TWA	: 8-hour Occupational exposure limit
CA BC OEL / TWA	: 8-hour time weighted average
CA QC OEL / TWAEV	: Time-weighted average exposure value

AICS - Australian Inventory of Chemical Substances; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Con-

**Ezetimibe / Simvastatin Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 04/24/2019
4.2	09/13/2019	28109-00014	Date of first issue: 11/04/2014

---

centration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

Sources of key data used to compile the Material Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Revision Date : 09/13/2019

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

CA / Z8